Business Context and Reporting Period
Company: EQUUS TOTAL RETURN, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: May 20, 2025
Event Date: May 15, 2025
Context: The Company reported receiving a notice from the New York Stock Exchange (NYSE) regarding non-compliance with continued listing standards due to low stock price.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Listing Status: The Company is currently not in compliance with NYSE Section 802.01C because the average closing price of its Common Stock was less than $1.00 over a consecutive 30 trading-day period.
- Immediate Impact: The notice does not result in immediate delisting. The Common Stock will continue to be listed and traded on the NYSE during the cure period.
- Operational Impact: Management states the notice is not anticipated to impact ongoing business operations or SEC reporting requirements.
Guidance, Outlook, and Management Commentary
- Cure Plan: The Company intends to notify the NYSE by May 25, 2025, of its plan to cure the deficiency. It has a six-month period to regain compliance.
- Compliance Criteria: To regain compliance, the Company must achieve a closing share price of at least $1.00 and an average closing share price of at least $1.00 over a 30 trading-day period ending on the last trading day of any calendar month within the cure period.
- Proposed Action: The Company is considering a reverse stock split. Authorization for this action has been proposed for the upcoming annual meeting of stockholders scheduled for June 26, 2025.
- Alternative Cure: If a reverse stock split requiring stockholder approval is pursued, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and remains above that level for at least 30 trading days.
Investor Verification Checklist
- Verify the outcome of the annual meeting of stockholders on June 26, 2025, regarding the proposed reverse stock split.
- Monitor the Company's stock price to ensure it meets the $1.00 threshold within the six-month cure period.
- Confirm the Company's formal notification to the NYSE regarding its cure plan by May 25, 2025.
- Review the press release (Exhibit 99.1) for any additional details on the non-compliance notice.